Is Cetrorelix FDA approved?

Cetrorelix is FDA approved (FDA status current as of 1999-06-03). This regulatory status is provided for research and educational context only.

How is Cetrorelix administered in research settings?

In research settings, Cetrorelix is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is Kisspeptin-10 administered in research settings?

In research settings, Kisspeptin-10 is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Cetrorelix vs Kisspeptin-10

Peptide Comparison

Cetrorelix vs Kisspeptin-10

Name: Cetrorelix vs Kisspeptin-10 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Reproductive & Hormonal peptides.

Cetrorelix

Cetrotide

Sexual HealthFDA ApprovedPrescription

Half-life: ~62 hours

1 providers listed

Full Cetrorelix profile →

Kisspeptin-10

KP-10

Sexual HealthUnder clinical reviewResearch Only

Half-life: ~4 minutes (3.8–4.1 min, human IV)

52 providers listed

Full Kisspeptin-10 profile →

Bottom line

Cetrorelix is FDA-approved, while Kisspeptin-10 is banned from compounding — the clearest structural difference between them.

Quick Verdict

Cetrorelix

Evidence

Established Clinical

Half-life

~62 hours

Kisspeptin-10

Evidence

Clinical

Half-life

~4 minutes (3.8–4.1 min, human IV)

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Cetrorelix
Further along in FDA review	Cetrorelix
Less frequent dosing (longer half-life)	Cetrorelix
More provider options (1 vs 52)	Kisspeptin-10

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Cetrorelix

Kisspeptin-10

Mechanism Family

Reproductive & Hormonal

Half-life

~62 hours

~4 minutes (3.8–4.1 min, human IV)

FDA Status

approved

Under clinical review

Admin Routes

subcutaneous

subcutaneous, intravenous

Availability

Prescription

Research Only

Providers

1 listed

52 listed

FDA Update

Jun 1999

Under clinical review

Avail. Notes

FDA-approved GnRH antagonist. Brand: Cetrotide (NDA 021036, Jun 1999). Prevents premature LH surges in controlled ovarian stimulation. Prescription only.

No FDA approval. Phase 1/2 studies for hypogonadotropic hypogonadism and IVF trigger (NIH/academic). No NDA filed. Sold as research peptide outside of clinical trials.

Research Evidence

Cetrorelix

Established ClinicalMeta-analysis · 7 key studies · most recent 2026

Kisspeptin-10

ClinicalRCT · 7 key studies · most recent 2026

Research Citations

Cetrorelix

Meta-analysis2026 · J Coll Physicians Surg Pak

GnRH Agonists and Antagonists in IVF/ICSI Cycles of PCOS Women: A Network Meta-Analysis.

Meta-analysis2023 · Hum Reprod Update

Optimal GnRH antagonist protocol for ovarian stimulation during ART: systematic review and network meta-analy…

Cohort2026 · Eur J Pharm Sci

Hydrogel and oleogel formulation of the decapeptide cetrorelix acetate for nasal administration.

Cohort2026 · Int J Reprod Biomed

Efficacy and safety of different cetrorelix doses in the luteal phase for preventing ovarian hyperstimulation…

+3 more

Kisspeptin-10

Cohort2026 · Neuropeptides

Kisspeptin-10 attenuates pulmonary arterial hypertension via restoration of mitochondrial function in pulmona…

Cohort2026 · Cytotechnology

Exogenous Kisspeptin-10 inhibits ovarian cancer progression through targeting the SP1-hTERT-ZEB1 regulatory a…

Cohort2026 · Cytotechnology

Exogenous Kisspeptin-10 inhibits ovarian cancer progression through targeting the SP1-hTERT-ZEB1 regulatory a…

Cohort2026 · Pharmacol Rep

Kisspeptin-10 regulates glycosaminoglycan and decorin content in human cardiac fibroblast cultures.

+3 more

About Cetrorelix

Competitive GnRH receptor antagonist; immediately blocks pituitary GnRH receptors; rapidly suppresses LH/FSH without initial flare effect; used for controlled hormonal suppression

Research Areas

HPG axis suppressionLH/FSH reductioncontrolled ovarian stimulation supporttestosterone management

About Kisspeptin-10

Activates GPR54/KISS1R receptor on GnRH neurons; triggers pulsatile GnRH release → LH/FSH surge → testosterone/estrogen production

Research Areas

GnRH neuron activation driving LH and FSH releaseovulation triggering studied in IVF clinical trialstestosterone and sperm production support in hypogonadotropic hypogonadismupstream HPG axis modulation above gonadorelin and hCG

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Cetrorelix

Absolute Contraindications

Pregnancy — contraindicatedLactation — contraindicated

Source: FDA label

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Kisspeptin-10

Reported (Unverified — Pending Clinical Review)

hormone-sensitive cancerspregnancy

No established clinical contraindications

Price (per mg)

Cetrorelix

Not enough vendor pricing yet.

Kisspeptin-10

$6.50/mg

$5.30 – $6.95 range

6 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

Cetrorelix

1 listed

Browse directory →

Providers offering

Kisspeptin-10

52 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Reproductive & Hormonal Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 27, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Cetrorelix vs Kisspeptin-10 — Per-mg Price Comparison. Retrieved July 29, 2026, from https://peptidebase.io/peptides/compare/cetrorelix/kisspeptin-10

https://peptidebase.io/peptides/compare/cetrorelix/kisspeptin-10 Methodology License Download JSON Download CSV